Application of bacteroides cellulosityticus in preparing a preparation for preventing and/or treating lipid metabolism related diseases

Patent metadata

Field	Value
Publication number	US-11273186-B2
Application number	US-201716642702-A
Country	US
Kind code	B2
Filing date	Aug 29, 2017
Priority date	Aug 29, 2017
Publication date	Mar 15, 2022
Grant date	Mar 15, 2022

Abstract

The present invention discloses an application of Bacteroides cellulosilyticus in preparing a preparation for preventing and/or treating lipid metabolism related diseases, such as atherosclerosis related diseases, cardiovascular diseases and obesity.

First claim

What is claimed is:

1. A method for treating lipid metabolism related diseases in a subject in need thereof, comprising administering to the subject a composition comprising a therapeutically effective amount of Bacteroides cellulosilyticus.

2. The method according to claim 1 , wherein the lipid metabolism related diseases are selected from the group consisting of atherosclerosis related diseases, cardiovascular diseases, obesity and a combination thereof.

3. The method according to claim 1 , wherein the Bacteroides cellulosilyticus is selected from the group consisting of Bacteroides cellulosilyticus DSM 14838, Bacteroides cellulosilyticus CL02T12C19, Bacteroides cellulosilyticus WH2 and a combination thereof.

4. The method according to claim 1 , wherein the Bacteroides cellulosilyticus is capable of one or more effects selected from the group consisting of:
(i) lowering blood lipid level in a mammal;
(ii) reducing body weight of a mammal;
(iii) relieving myocardial ischemia in a mammal; and
(iv) alleviating vascular lesions in a mammal.

5. The method according to claim 1 , wherein the Bacteroides cellulosilyticus or the composition is administrated orally.

6. The method according to claim 1 , wherein the administration dosage is 0.01 to 5 g/50 kg body weight per day.

7. The method according to claim 1 , wherein the subject is a human or non-human mammal, wherein the non-human mammal is a mouse, rat or primate.

8. The method according to claim 1 , wherein the composition further comprises one or both of probiotics and prebiotics.

9. The method according to claim 8 , wherein the probiotics are selected from the group consisting of Lactic acid bacteria, Bifidobacteria, Lactobacillus acidophilus and a combination thereof.

10. The method according to claim 8 , wherein the prebiotics are selected from the group consisting of fructooligosaccharide (FOS), galactooligosaccharide (GOS), xylooligosaccharide (XOS), lactosucrose (LACT), soybean oligosaccharides (SOS), Inulin, oligosaccharide and a combination thereof.

11. The method according to claim 1 , wherein the composition further comprises a substance capable of maintaining the viability of Bacteroides cellulosilyticus.

12. The method according to claim 11 , wherein the substance capable of maintaining the viability of Bacteroides cellulosilyticus is selected from the group consisting of cysteine, glutathione, butyl hydroxyanisole, dibutylmethyltoluene, tocopherol, antioxidant of bamboo, D-isoascorbic acid and sodium salt thereof, sodium ascorbate, calcium ascorbate, phospholipid, Vitamin C (ascorbic acid), Vitamin E and a combination thereof.

13. The method according to claim 11 , wherein the substance capable of maintaining the viability of Bacteroides cellulosilyticus is of a weight ratio (wt%) of 0.1% to 2%, based on the total weight of the composition.

14. The method according to claim 1 , wherein the composition further contains a growth factor.

15. The method according to claim 1 , wherein the composition contains 1×10-1×10 15 cfu/mL or cfu/g of Bacteroides cellulosilyticus , based on the total volume or total weight of the composition.

16. The method according to claim 1 , wherein the composition is in a unit dosage form selected from the group consisting of one tablet, one capsule and one vial, and wherein the composition in each unit dosage form is of a mass of 0.05 g to 5 g.

17. The method according to claim 2 , wherein the atherosclerosis related diseases are selected from the group consisting of coronary heart disease, coronary artery disease (CAD), atherosclerotic heart disease, atherosclerotic cardiovascular diseases, ischemic heart disease and a combination thereof.

18. The method according to claim 1 , wherein the composition further comprises a food acceptable or pharmaceutically acceptable carrier.

19. The method according to claim 18 , wherein the food acceptable or pharmaceutically acceptable carrier comprises excipient, lubricant, wetting agent, emulsifier, suspension stabilizer, preservative, sweetener or flavor.

20. The method according to claim 1 , wherein the composition is a food composition, a health care composition, a pharmaceutical composition, a beverage composition, a feed composition or a combination thereof,
wherein the composition is of a dosage form selected from the group consisting of powder, pulvis, tablet, sugar coating agent, capsule, granule, suspension, solution, syrup, drop and sublingual tablet.

Assignees

• Bgi Shenzhen

Inventors

• Jie Zhuye
• Liang Suisha
• Xia Huihua
• Zou Yuanqiang
• Xiao Liang
• Jia Huijue

Classifications

• A61K36/06

  Fungi, e.g. yeasts · CPC title

• A61K35/20

  Milk; Whey; Colostrum · CPC title

• A61K31/7016

  Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032) · CPC title

• A23L33/135

  Bacteria or derivatives thereof, e.g. probiotics · CPC title

• A23K50/50

  for rodents · CPC title